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The stage-specific antimalarial activities of a panel of antiretroviral protease inhibitors (PIs), including
two nonpeptidic PIs (tipranavir and darunavir), were tested in vitro against Plasmodium falciparum. While
darunavir demonstrated limited antimalarial activity (effective concentration [EC50], >50 M), tiprana-
vir was active at clinically relevant concentrations (EC50, 12 to 21 M). Saquinavir, lopinavir, and
tipranavir preferentially inhibited the growth of mature asexual-stage parasites (24 h postinvasion). While
all of the PIs tested inhibited gametocytogenesis, tipranavir was the only one to exhibit gametocytocidal
activity.
The global distributions of HIV and malaria overlap in
many regions of the world (reviewed in reference 17). Al-
though data on the number of individuals with both diseases
are unavailable, rates of coinfection are likely to be high (7).
Furthermore, coinfection often leads to severe disease (4,
12, 19, 20). While the effects of antiretroviral therapy on the
outcome of malaria infection are not understood, defining
these interactions is important (11, 13, 16, 18). Understand-
ing the antimalarial activities of the antiretroviral protease
inhibitors (PIs) (reviewed in reference 17), for example, may
lead to treatment recommendations that improve clinical
outcomes and may also result in the identification of a new
antimalarial drug target.
Current data suggest that PIs kill malaria parasites by inhib-
iting one or more of the six nondigestive vacuole plasmepsins
(reviewed in reference 17). In the present study we investigated
the stage-specific effects of the PIs on asexual- and sexual-stage
Plasmodium falciparum parasites in order to help define the
antimalarial target(s) of these drugs and to help guide partner
drug choices in the field. To gain additional structure-activity
data and information that may be relevant for coinfected in-
dividuals we also examined the activities of the nonpeptidic PIs
tipranavir (Aptivus) and darunavir (Prezista), new-generation
PIs that are active against HIV-1 strains resistant to first gen-
eration PIs (9).
The antimalarial activities of saquinavir, lopinavir, ritonavir,
tipranavir, darunavir, and chloroquine (diphosphate salt;
Sigma) were determined as described previously (18). Concen-
trations required to achieve 10, 50, and 90% growth inhibition
( the standard error [SE]) were determined by nonlinear
regression curve fitting. Each assay was performed in triplicate
on at least two separate occasions. Stage-specific growth inhi-
bition assays were performed on synchronized parasite cultures
(8) at 0 (ring), 24 (trophozoite), and 36 h (schizont) postsyn-
chronization. Cultures were washed post-drug exposure, resus-
pended in drug-free medium, and seeded into tissue culture
plates containing 0.5 Ci/well [3H]hypoxanthine for 40 h. In-
corporation of [3H]hypoxanthine was compared to that in
vehicle controls.
Drug-induced effects on gametocytogenesis were examined
using Pfs16-GFP parasites (3) as previously described (14).
Assays were performed in triplicate on three separate occa-
sions. The antigametocyte activities of selective PIs were also
determined using Pfs16-GFP parasites (3). In these assays
gametocytes were sorted from parasite cultures, seeded into
microtiter plates (1,000 gametocytes and 5% hematocrit), and
exposed to drugs or controls for 48 h. Hydroethidine was used
to assess viability. The number of viable gametocytes in test
cultures after treatment was compared to controls, and results
were analyzed by one-way analysis of variance. Assays were
performed in triplicate on two separate occasions.
Tipranavir was active against all parasite lines tested, includ-
ing the chloroquine-resistant line Dd2 (50% effective concen-
tration [EC50], 212 M) and three chloroquine-sensitive
lines (3D7, EC50 of 202 M; D10, EC50 of 122 M; Pfs16-
GFP, EC50 of 184 M). These EC50s are all below the Cmin
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to Cmax range (60 to 185 M) for this drug in humans (6).
Darunavir also inhibited the growth of P. falciparum. However,
the EC50 (Dd2 EC50 of 70 M) (data not shown) for this drug
was well above clinically achievable levels (Cmin to Cmax, 0.7 to
12.4 M) (5). The EC50s of saquinavir (D10 EC50, 3  1 M;
3D7 EC50, 3  3 M; Pfs16-GFP EC50, 5  3 M), lopinavir
(D10 EC50, 2  1 M; 3D7 EC50, 2  3 M; Pfs16-GFP EC50,
3  1 M), ritonavir (D10 EC50, 3  1 M; 3D7 EC50, 3  1
M; Pfs16-GFP EC50, 5 1 M) and chloroquine (D10 EC50,
23  1 nM; 3D7 EC50, 25  6 nM; Pfs16-GFP EC50, 23  3
nM) were comparable between parasite lines and similar to
previously published values for 3D7 (1, 2).
Saquinavir, lopinavir, and tipranavir demonstrated signifi-
cantly greater growth inhibition (P  0.05) against trophozoite
and schizont stages in comparison to ring stages (Fig. 1). Sim-
ilar results were obtained for the drug-resistant Dd2 P. falcip-
arum line (data not shown). Chloroquine was used as a control
and, as expected, trophozoite stages were more sensitive to this
drug than either ring or schizont stages (Fig. 1). Each of the
four PIs tested also reduced the number of gametocytes pro-
duced in vitro (Fig. 2A). The reduction in gametocytes was
dose dependent and statistically significant (P  0.01) when
cultures were exposed to EC90 levels of ritonavir and all con-
centrations of tipranavir (Fig. 2A). Tipranavir was also able to
directly kill gametocytes (Fig. 2B) (P  0.01). While saquina-
vir, ritonavir, and lopinavir reduced the numbers of live game-
tocytes in a dose-dependent fashion, these data did not reach
statistical significance (Fig. 2B) (P  0.05).
Evidence suggesting that PIs may be beneficial to HIV
and malaria parasite-coinfected individuals is mounting. In
addition to possessing antiretroviral activities these drugs
also inhibit the growth of malaria parasites (1, 13, 15, 18). In
the present study we have extended these data by demon-
strating that tipranavir can inhibit the growth of malaria
parasites at clinically relevant concentrations (6). Although
additional studies, including those examining pharmacoki-
netic drug interactions and the effects of increased plasma
proteins on the activity of tipranavir, are needed (6), these
data further indicate that PIs are likely to be beneficial
during HIV-malaria coinfection. The antigametocyte activ-
ity demonstrated by tipranavir adds an additional dimension
to this observation, suggesting that this drug may also have
an impact on malaria transmission. These data are novel in
that very few antimalarial drugs have antigametocyte activ-
ity. Indeed most induce gametocytogenesis in vitro (14) and
as a result can perpetuate transmission and the spread of
drug-resistant parasites. The observation that none of the
PIs induced gametocytogenesis in vitro is significant, given
recent malaria eradication goals and the need for tools to
achieve this (10).
To gain an understanding of how HIV PIs kill P. falciparum
we investigated their effects on individual stages of asexual
development. Data from these studies indicated that the tro-
phozoite and schizont stages are significantly more sensitive to
PIs than ring-stage parasites (Fig. 1). Taken together with
gametocyte inhibition data these results suggest that the pri-
mary target of the PIs is likely to be expressed in both game-
tocytes and intraerythrocytic parasites. Although expression
data (http://plasmodb.org/) require confirmation and the pos-
sibility that the PIs might target different proteases in the
different parasite stages cannot be ruled out, plasmepsins V,
IX, and X appear to be the best candidate targets of these
drugs. Future studies investigating these enzymes may identify
the antimalarial target of the PIs and help explain the poor
antimalarial activity of darunavir. Interestingly, darunavir has a
FIG. 1. In vitro stage-specific activities of PIs against P. falciparum asexual parasites. Erythrocytes infected with P. falciparum line D10 at ring
(filled circles) trophozoite (open circles), or schizont (filled squares) stages were exposed to saquinavir (SQV; 40 M), tipranavir (TPV; 150 M),
lopinavir (LPV; 20 M), and chloroquine (CHQ; 50 nM) for 1, 2, 4, 6, or 8 h, as described in the text. Data are presented as percent growth
inhibition (SE) compared to vehicle controls (taken as 100% growth). Each assay was repeated twice in triplicate.
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similar structure to amprenavir, another PI with weak antima-
larial activity (5, 18).
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